A Clinical Trial Comparing Treatment With Cangrelor (in Combination With Usual Care) to Usual Care, in Subjects Who Require Percutaneous Coronary Intervention (PCI).

Trial Profile

A Clinical Trial Comparing Treatment With Cangrelor (in Combination With Usual Care) to Usual Care, in Subjects Who Require Percutaneous Coronary Intervention (PCI).

Discontinued
Phase of Trial: Phase III

Latest Information Update: 19 Mar 2017

At a glance

  • Drugs Cangrelor (Primary) ; Clopidogrel
  • Indications Acute coronary syndromes; Angina pectoris; Coronary disorders; Myocardial infarction
  • Focus Pharmacodynamics; Registrational; Therapeutic Use
  • Acronyms CHAMPION-PLATFORM
  • Sponsors The Medicines Company
  • Most Recent Events

    • 17 Jan 2017 Results of a subgroup analysis of CHAMPION PCI, CHAMPION PLATFORM and CHAMPION PHOENIX trials (n=24,902) in patients who did not receive Glycoprotein IIb/IIIa Inhibitors, presented in the Journal of the American College of Cardiology
    • 24 Aug 2015 According to The Medicines Company media release, data from this study will be presented at the 2015 European Society of Cardiology (ESC) Congress.
    • 14 Nov 2014 The Medicines Company plans to resubmit an NDA for cangrelor by the end of 2014 with respect to the PCI indication, according to a media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top